© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Zenocutuzumab targets tumors with a specific genetic alteration, making it potentially active against cancer at multiple locations.
MRTX849 shrank tumors in half of lung cancer patients with a common but difficult to target mutation.
Here’s a list of the approved drugs to treat lung cancer. Click on any of the medications for more info on dosing, side effects and d...
The investigational machine has an 85% accuracy rate.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
People who paid more money out-of-pocket filled fewer prescriptions and had shorter overall survival.
FDA approves Rozlytrek for cancers with certain gene mutations
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
Selpercatinib shrank tumors in 68% of patients previously treated with chemotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
